Dr. Reddy's Laboratories Ltd. has launched Sevelamer Carbonate Tablets in the U.S. market, according to the drug maker's notification to the exchanges.
The blockbuster drug is a therapeutic equivalent generic version of Renvela tablets, approved by the U.S. Food and Drug Administration. It is used to lower high blood phosphorus (phosphate) levels in patients who are on dialysis due to severe kidney disease.
The Renvela brand and generic has U.S. annual sales of approximately $1.88 billion, the company said quoting IMS Health's July data. This was the company's eighth overall and fourth limited-competition launch this fiscal year.
Also Read: Dr. Reddy's Unlikely To Meet U.S. Launch Guidance In FY18, HSBC Says
Essential Business Intelligence, Continuous LIVE TV, Sharp Market Insights, Practical Personal Finance Advice and Latest Stories — On NDTV Profit.
